- Press Release -

Rockville, Md. The global peptide based gastrointestinal disorders therapeutics market is set to surpass US$ 600 Mn by 2022 on strong growth, according to Fact.MR, as rising gastrointestinal and metabolic ailments push physicians toward more effective therapies. Drug makers are increasingly partnering with medical research centers to develop better peptide drugs, and structural advances in peptide synthesis are behind encouraging preclinical results.

North America leads the market, linaclotide dominates by drug, and hospital pharmacies carry most sales.

Drugs, Channels and Regions

Linaclotide is the leading drug at over two-thirds of revenue, with more than US$ 466 Mn expected to sell by 2022. On distribution, hospital pharmacies hold nearly 50% of revenue and stay dominant through the period, while retail pharmacies rank second and post impressive growth.

North America holds the largest revenue share and is expected to expand at just under a 14% CAGR, on rising adoption of peptide drugs and growing patient awareness of novel treatments.

Clinical Need Drives Demand

The market runs on unmet need and innovation. As gastrointestinal disorders grow more common, the case for efficient peptide therapies strengthens, and ongoing work to improve peptide stability and half-life is helping overcome earlier limitations, though high peptide complexity remains a challenge for manufacturers.

Suppliers and Their Playbook

The field brings together specialty pharmaceutical companies.

• Ironwood Pharmaceuticals, Inc., Allergan plc, Shire plc, Astellas Pharma Inc., and Accredo Health Group, Inc. are among the key players in the report.

Reading the Market for Decisions

For drug makers, growth favours continued development of efficacious peptide drugs. Investors get a small, fast-growing market concentrated in North America. Procurement and pharmacy teams can plan around linaclotide carrying volume, hospital pharmacies leading distribution, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global peptide based gastrointestinal disorders therapeutics market for the 2017 to 2022 forecast period, with segmentation by drug, distribution channel and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the peptide based gastrointestinal disorders therapeutics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.